Answers are grounded in this paper and cite their sources.
Rehmapicrogenin, a bioactive constituent of Rehmannia glutinosa , has drawn increasing interest owing to its pronounced anti‐inflammatory activity. In this study, a rapid and sensitive ultra‐high‐performance liquid chromatography tandem mass spectrometry (UPLC–MS/MS) method was established and validated for the quantification of rehmapicrogenin in mouse plasma. Plasma samples were prepared by a one‐step protein precipitation using acetonitrile acidified with 2 mM HCl. Chromatographic separation was achieved on an Acquity HSS T3 column and detection was carried out on a triple quadrupole tandem mass spectrometer operating in negative ionization mode under multiple‐reaction monitoring (MRM) transitions of m/z 183.1 → 139.1 for rehmapicrogenin and m/z 345.2 → 123.1 for the internal standard. The method exhibited good linearity across 10–5000 ng/mL. The assay was validated in accordance with the FDA guidance and the ICH M10 guideline. The validated assay was subsequently applied to pharmacokinetic and bioavailability investigations in mice. Following intravenous administration, rehmapicrogenin was eliminated with a low clearance and showed limited distribution into tissues. After oral administration, the absolute bioavailability ranged from 39.13% to 48.81% over the 5–20 mg/kg dose range. These findings provide a methodological foundation and reference parameters that should facilitate future pharmacokinetic–pharmacodynamic investigations of this compound.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: